 Scientist on Computer_edited_edited |
|---|
 Conference |
 Add a Title |
 icon_PrIMAVeRA_crop |
 Laboratory |
 Drug and Syringe |
 Girl at the Pediatrician |
 Pipetting Samples |
 hand shake_Inno4Vac KoM_Source Wix |
 Add a Title |
 Preventive services |
 Add a Title |
PrIMAVeRa
In-silico tools to evaluate the effect of vaccines on reduction of AMR
‘PrIMAVeRa’ means ‘Predicting the Impact of Monoclonal Antibodies & Vaccines on Antimicrobial Resistance’.
​
It is a European project funded by the Innovative Medicines Initiative 2 (IMI2) with the goal of developing an open-source, web-based platform combining mathematical models with a comprehensive epidemiological repository (i.e., with data referring to health and economic outcomes). This platform will aim to enable policymakers to reach data-driven decisions regarding the prioritisation of specific vaccines and monoclonal antibodies (mAbs), informing the strategic allocation of limited resources.
​
A project sustainability plan will also be designed by the project partners with the goal of providing long-term access to the project results, including the models, once the project has finished.
​
PRIMAVERA is part of the AMR Accelerator Programme.
Contact
For PrIMAVeRa inquiries, please contact:
European Vaccine
Initiative (EVI)
Coordination
Project Leader: Irina Meln
UniversitätsKlinikum Heidelberg
Voßstraße 2, Geb. 4040
69115 Heidelberg, Germany